Pregnancy is a time of excitement and anticipation for expectant parents, but it can also come with serious health risks. Complications such as preeclampsia and preterm birth can endanger the well-being of both the parent and the unborn child. Currently, doctors rely on limited measures to determine the risk of these complications, but advancements in genetic testing may provide a more precise and early detection method.
Scientists have discovered that free-floating genetic material, known as cell-free DNA and RNA, found in a pregnant person’s blood can potentially reveal the presence of complications like preeclampsia and preterm birth. Unlike DNA, RNA offers a dynamic view of gene activity over time, allowing researchers to monitor changes that occur during pregnancy. This new approach not only provides a potential diagnostic tool but also offers insights into the underlying biology of these conditions.
Studies have shown that analyzing cell-free RNA from both the mother and child can help identify the risk of complications. Researchers have identified specific RNA markers associated with preeclampsia and preterm birth and have even developed tests to predict the likelihood of these conditions. For example, a test based on 18 genes measured before 16 weeks of pregnancy accurately predicted the risk of preeclampsia in a group of women.
These advancements in genetic testing have the potential to revolutionize the way doctors approach pregnancy complications. By defining subtypes of preeclampsia and preterm birth based on molecular signatures, physicians can personalize treatment and improve outcomes for patients.
While RNA-based tests for preeclampsia and preterm birth are still in the development stage, progress is being made towards their clinical implementation. Companies like Mirvie are conducting large studies to validate these tests and bring them to the market.
In conclusion, the discovery of using cell-free RNA as a diagnostic tool for pregnancy complications holds great promise. With further research and validation, these tests could significantly improve the monitoring and treatment of conditions like preeclampsia and preterm birth, ultimately ensuring the health and well-being of both parent and child.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
